Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
Kuuliala A, Leirisalo-Repo M, Möttönen T, Hannonen P, Nissilä M, Kautiainen H, Korpela M, Julkunen H, Hakola M, Repo H; FIN-RACo Trial Group. Kuuliala A, et al. Among authors: korpela m. Clin Exp Rheumatol. 2005 Mar-Apr;23(2):243-6. Clin Exp Rheumatol. 2005. PMID: 15895898 Clinical Trial.
Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis.
Kuuliala K, Orpana A, Leirisalo-Repo M, Kautiainen H, Hurme M, Hannonen P, Korpela M, Möttönen T, Paimela L, Puolakka K, Karjalainen A, Repo H. Kuuliala K, et al. Among authors: korpela m. Ann Rheum Dis. 2006 Sep;65(9):1241-3. doi: 10.1136/ard.2006.055137. Epub 2006 Apr 10. Ann Rheum Dis. 2006. PMID: 16606645 Free PMC article. Clinical Trial.
Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.
Laivoranta-Nyman S, Möttönen T, Hannonen P, Korpela M, Kautiainen H, Leirisalo-Repo M, Julkunen H, Luukkainen R, Hakala M, Vuori K, Laine AP, Toivanen A, Ilonen J; FIN-RACo Trial Group. Laivoranta-Nyman S, et al. Among authors: korpela m. Clin Exp Rheumatol. 2006 Nov-Dec;24(6):636-42. Clin Exp Rheumatol. 2006. PMID: 17207378 Clinical Trial.
Cost of Finnish statutory inpatient rehabilitation and its impact on functional and work capacity of patients with early rheumatoid arthritis: experience from the FIN-RACo trial.
Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Pohjolainen T, Korpela M, Vuori K, Ilva K, Yli-Kerttula U, Järvinen P, Leirisalo-Repo M. Puolakka K, et al. Among authors: korpela m. Scand J Rheumatol. 2007 Jul-Aug;36(4):270-7. doi: 10.1080/03009740701286847. Scand J Rheumatol. 2007. PMID: 17763204 Clinical Trial.
Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
Hakala M, Risteli J, Aman S, Kautiainen H, Korpela M, Hannonen P, Leirisalo-Repo M, Laasonen L, Paimela L, Möttönen T; Fin-Raco Trial Group. Hakala M, et al. Among authors: korpela m. Scand J Rheumatol. 2008 Mar-Apr;37(2):90-3. doi: 10.1080/03009740701753689. Scand J Rheumatol. 2008. PMID: 18415764 Clinical Trial.
179 results